RxDoctor Payments Data

Alan Kaye, MD

Pain Medicine · New Orleans, LANPI 1447292370

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $45,625 of the $75,873 with a category attached, or 60.1%. Merck accounts for 61.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $41,911 and has fallen 70.3% since, to $12,444 in 2025. Among pain medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,873in general payments, 2019–2025

Across 147 payments — averaging $516.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$47K
  • Vertex$12K
  • Collegium Pharmaceutical, Inc.$9K
  • Eisai Inc.$4K
  • Boston Scientific$2K
  • Nevro Corp.$521
  • plus $2K from 16 others
$4,497in research payments, 2019–2025

Across 2 payments — averaging $2248.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$2K
  • Purdue Pharma L.p.$2K

What the payments were for

  • Consulting fees$13,17517%
  • Speaking & faculty fees$45,62560%
  • Travel & lodging$12,05716%
  • Food & beverage$5,0167%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,873 in reported general payments places this provider in the 95th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$17,043
Medicare patients
57
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pain medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →